Article
Alcaftadine ophthalmic solution 0.25% (Lastacaft, Vistakon) has been approved by the FDA for the prevention of itching associated with allergic conjunctivitis in patients aged more than 2 years.
Jacksonville, FL-Alcaftadine ophthalmic solution 0.25% (Lastacaft, Vistakon) has been approved by the FDA for the prevention of itching associated with allergic conjunctivitis in patients aged more than 2 years.
The H1 histamine receptor antagonist also inhibits the release of histamine from mast cells.
In clinical trials, the most common side effects were eye irritation, burning and/or stinging on instillation, eye redness, and eye itching. They occurred in less than 4% of alcaftadine-treated eyes.
The most common non-ocular side effects were nasopharyngitis, headache, and influenza. They occurred in less than 3% of patients with alcaftadine-treated eyes.
The ophthalmic solution is packaged in 5-ml bottles containing 3 ml alcaftadine 0.25% (2.5 mg/ml) preserved with benzalkonium chloride. The recommended dosage of alcaftadine is one drop in each eye once daily.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.